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Background: Osteosarcoma (OS) is a prevalent primary malignant bone tumour with unknown etiology. These
highly metastasizing tumours are among the most frequent causes of cancer-related deaths. Thus, there is an
urgent need for different markers, and with our study, we were aiming towards finding novel biomarkers for OS.
Methods: For that, we analysed the whole exome of the tumorous and non-tumour bone tissue from the same
patient with OS applying next-generation sequencing. For data analysis, we used several softwares and combined
the exome data with RNA-seq data from our previous study.
Results: In the tumour exome, we found wide genomic rearrangements, which should qualify as chromotripsis—
we detected almost 3,000 somatic single nucleotide variants (SNVs) and small indels and more than 2,000 copy
number variants (CNVs) in different chromosomes. Furthermore, the somatic changes seem to be associated to
bone tumours, whereas germline mutations to cancer in general. We confirmed the previous findings that the most
significant pathway involved in OS pathogenesis is probably the WNT/β-catenin signalling pathway. Also, the IGF1/
IGF2 and IGF1R homodimer signalling and TP53 (including downstream tumour suppressor gene EI24) pathways
may have a role. Additionally, the mucin family genes, especially MUC4 and cell cycle controlling gene CDC27 may
be considered as potential biomarkers for OS.
Conclusions: The genes, in which the mutations were detected, may be considered as targets for finding
biomarkers for OS. As the study is based on a single case and only DNA and RNA analysis, further confirmative
studies are required.
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Osteosarcoma (OS) is a most prevalent primary malig-
nant bone tumour and mostly occurs in children and
adolescents—75% of patients with OS are 15 to 25 years
old. The etiology is unknown; however, a genetic predis-
position has been suggested [1,2]. Reviewed in [3], these
tumours have high potential to metastasize and are one
of the most frequent causes of cancer-related deaths.
The survival rate increased up to 70% after chemotherapy
became available [4]. However, no further improvements* Correspondence: ene.reimann@ut.ee
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Thus, the survival plateau forces scientists to look for
new biomarkers (diagnostic, disease monitoring, re-
sponse, resistance markers, drug targets), which could
lead to, i.e. applying new therapeutic agents. While OS
is rare and very heterogeneous (inter-patient, inter-
tumour and intra-tumour heterogeneity), the clinical
study progress is slow; thus, the preclinical studies are
vital. Furthermore, finding the biomarkers and detect-
ing the potential targets for new drugs are essential to
improve the present situation.
There are several next-generation sequencing (NGS)
and genome-wide association studies (GWAS) about
OS, which associate different genes and pathways with
pathogenesis of OS [5-7]. With whole exome sequencingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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TP53, PTEN and PRB2 are found to be mutated in sig-
nificant frequency [5]. High mutation rate in TP53 has
also demonstrated in OS cell lines. Additionally, deletion
of CDKN2A/B locus and amplification of MDM2 were
detected [8]. With GWAS studies, a single nucleotide
variant (SNV) in GRM4 was detected as potential bio-
marker for OS [7]. Gene expression studies reveal that, i.
e. WNT inhibitory factor (WIF1) has a loss of expression
in OS cell lines [9]; however, we found in our previous
work that the expression has increased significantly [10].
Thus, as demonstrated, the expression pattern of WNT
pathway genes in different OS cases may not be similar.
When correlating the expression patterns of miRNA/
mRNA pairs, miRNAs regulating TGFBR2, IRS1, PTEN
and PI3K have been detected [11]. In addition, several
serine/threonine kinases (mechanistic target of rapamy-
cin (mTOR)) or tyrosine kinases (SRC, IGF1R, PDGFR,
KIT) are considered as targets in OS treatment [3,12,13].
When observing the related pathways, the WNT/β-ca-
tenin pathway is one of the most thoroughly studied
among bone malignancies. For example, the tumour
growth is regulated through this pathway and the over-
expression of BMP9 suppresses its activity [14,15]. Fur-
thermore, PI3K/AKT/mTOR signalling pathway was
brought forward as a potential target for therapy, and
also, pathways associated to TP53 may be altered [5].
Hypoxia-HIF-1α-CXCR4 pathway plays a crucial role
during the migration of human osteosarcoma cells [16].
These are just a few examples—the network of associ-
ated genes and pathways is complex.
OS has a very unstable genome—it may contain aberrant
number of chromosomes, and in most cases, these chro-
mosomes display major structural abnormalities including
amplification, deletions and translocations. For example,
several studies have demonstrated the gain of chromosomal
arms 6p, 8q and 17p in the case of OS [17,18]. To be more
precise, i.e. VEGFA amplification and LSAMP deletion have
been detected in OS [19,20]. Thus, it is suggested that gen-
omic instability is linked to the development of this tumour
[18,21-23]. Furthermore, the genomic aberrations are more
frequent in metastases than in primary tumours [24]. The
genes responsible for cell cycle regulation are suggested to
be associated to DNA breakage and genomic instability, i.e.
CDC5L overexpression and mutations in TP53 gene are
correlated to the high genomic instability in OS [23,25].
Moreover, the chromothripsis event is characteristic to
OS—it generates new fusion products. This may explain
the sudden onset of OS and the complexity and heterogen-
eity of OS genome [26]. All these changes make it difficult
to find biomarkers suitable for targeting OS, as there are so
many different subtypes.
In the present work, we analysed the whole exome of
the tumorous and non-tumour bone tissue from thesame patient with osteosarcoma. We used next-generation
sequencing to study how the coding region of the tumour
genome has altered. Additionally, we analysed together




The protocols and informed consent form used in this
study were approved by the Ethical Review Committee
on Human Research of the University of Tartu. The pa-
tient signed a written informed consent, which also in-
cludes the acceptance of the report to be published. A
16-year-old Caucasian male patient with an OS diagnosis
was studied. In more detail, the patient became ill with
complaints of pain in the left knee area. History of
trauma was missing, and GP administered painkillers
and vitamins. After 6 months, the patient returned to
GP with complaints of pain, swelling and dysfunction in
the left distal femur and knee area. The swelling line was
observed in the left femoral distal region, and the area
was thicker and painful to touch. No changes in skin
colour were detected. The X-ray investigation showed
additional shading and structural change in the distal
part of the left femur. For detailed investigation, the
MRI was performed and as a result, malignant process
was suspected. Patient was hospitalized, and bone biopsy
was taken for histological investigation. The diagnosis of
osteosarcoma was confirmed. Chemotherapy for osteo-
sarcoma started by Scandinavian Sarcoma Group (SSG)
XIV treatment protocol. The patient responded well to
the therapy—the histological analysis confirmed the nec-
rotic tissue in tumour. After 3 month of chemotherapy,
surgical removal of tumour (distal part of femoral bone
with knee joint) and replacement of the knee and the
lower part of the femur with megaprosthesis was per-
formed. Pathologist confirmed that resection line was
without tumour cells and OS was referred as NAS (Not
Further Specified). After the patient had recovered from
surgery, the SSG XIV chemotherapy treatment protocol
was followed. Materials for this study were collected
from the surgically removed tissue.
Exome sequencing
The genomic DNA (gDNA) was extracted from two
bone samples from different locations—one sample from
tumour area and another sample from the uninvolved
normal bone tissue as a control. For gDNA extraction,
the tissue was homogenized applying liquid nitrogen and
a mortar, and after that, the PureLink Genomic DNA kit
(Life Technologies Corp., Carlsbad, CA, USA) was used
according to manufacturer’s protocol. The Target Seq
Exome Enrichment System and SOLiD 5500 barcoded
adaptors (Life Technologies Corp., Carlsbad, CA, USA)
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platform and paired-end DNA sequencing chemistry
(75 bp forward and 35 bp reverse direction) were applied
to sequence the samples.
The data analysis
Offline cluster was used for data processing and analysis.
For bioinformatic analysis, LifeScope version 2.5 was ap-
plied. LifeScope performed colour space mapping and
pairing. Tertiary analysis consisted of SNV discovery
(diBayes algorithm) and detection of small indels. Hg19
(GRCh37.p13) was used as a reference, and before map-
ping, the multifasta file was verified in order to increase
the mapping quality.
The SNVs and small indel .gff3 files were used as input
in ANNOVAR software (AS; www.openbioinformatics.
org/annovar/) [27] and Ingenuity Variant Analysis (IVA;
http://www.ingenuity.com) QIAGEN, Redwood City,
MD, USA) software. Applying refGene hg19, dbSNP135
and dbCOSMIC67 databases, AS annotated and pre-
dicted the effects of SNVs and small indels we detected
in our study samples. AS also provides other prediction
tools in order to get prediction scores (PolyPhen-2, SIFT,
ljb2 etc.) [28-30]. Comparative distribution of SNVs and
small indels between different samples was performed
with Galaxy software bundle [31,32]. IVA provided tools
to annotate SNVs and small indels, which may be associ-
ated to cancer. The tumour and control samples were
compared, and the lists for diseases, processes and path-
ways related to cancer were received as output.
The .bam and .bai files were used as input in CEQer soft-
ware (CS) (www.ngsbicocca.org/html/ceqer.html), which is
a tool for analysing copy number variants (CNVs) and loss
of heterozygosity (LOH).
About the RNA-seq data analysis, please see our previ-
ous article, where we used the bone samples from the
same patient [10].
Results
For comparing the tumour tissue and non-tumour tissue
(control tissue) from the same individual, different ap-
proaches were applied. After mapping the data to a ref-
erence genome, we used several tools to perform the
tertiary analysis.
Sequencing statistics from LifeScope software
In the case of the tumour tissue, over 130 million (58%)
mappable reads were in target and the enrichment fold was
48%. Eighty-five percent of the detected targets were cov-
ered over 20 times, and the average coverage was 185.5. In
the case of the control tissue, over 154 million (61%) map-
pable reads were in target and the enrichment fold was
51%. Eighty-three percent of the detected targets were cov-
ered over 20 times, and the average coverage was 157.SNVs, small indels and CNVs
1) Results from ANNOVAR software
Using refGene hg19 database, AS was able to annotate
37,990 SNVs and 1,484 small indels. In the case of SNVs,
we considered the data reliable, if the coverage was over
20; thus, 25,914 SNVs remained. In the case of SNVs,
there were 23,767 germline mutations (9,067 in homozy-
gous form and 14,700 in heterozygous form) and 2,147
somatic mutations (in the tumour tissue—116 in homo-
zygous form and 2,031 in heterozygous form) (Table 1,
Additional file 1). Furthermore, there were 896 germline
small indels (278 in homozygous form and 618 in het-
erozygous form) and 588 somatic indels (in the tumour
tissue—177 in homozygous form and 411 in heterozy-
gous form).
Applying dbSNP135, we were able to annotate 5,281
SNVs and 239 small indels. With dbCOSMIC67, we an-
notated 2,569 SNVs and 59 small indels—none of these
were noted to be associated to bone cancer. Applying
ljb2 database, we found 469 SNVs to potentially cause a
disease (average ljb2 score over 0.918), including 31
germline mutations and 4 somatic mutations (ESX1: c.
A578G/p.K193R; CDC27: c.A17G/p.E6G; TMEM120B:
c.G274A/p.D92N; TMEM131: c.C3947T/p.P1316L) in
homozygous form in the tumour tissue.
2) Results from Ingenuity Variant Analysis software
Altogether, 207 cancer driver variants (CD-SNVs) were
found in 123 genes according to IVA (Additional file 2).
Fourteen CD-SNVs potentially gain and 186 lose the
gene function. Only seven SNVs may have no drastic
effect on gene function in the tumour tissue. Further-
more, according to IVA, none of these 207 SNVs affect
the gene functionality in the control tissue. Thirteen of the
CD-SNVs were homozygous in the tumour tissue (Table 2).
There were no cancer-associated homozygous mutations
present in the control tissue; thus, the homozygous
CD-SNVs in the tumour tissue are all somatic.
According to IVA, six cancer-associated small indels
were found (Table 2). Four of them are homozygous and
two are heterozygous in the tumour tissue—the effect is
most probably the loss of gene function. These indels
are predicted to have no effect in the control tissue.
In most of the genes brought front by IVA, one CD-
SNV was found in coding region in heterozygous form.
However, some of the genes have more CD-SNVs in cod-
ing regions: MUC4 had even 22, ZNF717 had 8, CTBP2
had 7 and OR4C3 had 5 CD-SNVs, whereas these were
not present in the control tissue (data not shown). When
observing from a slightly different angle—the gene com-
plexes, we can see that the mucin complex has the highest
Table 1 The numbers of SNV and small indel findings received from data analysis with ANNOVAR software






















Altogether 9,067 14,700 48 237 68 1,794
Exonic (includes ncRNA) 5,244 8,702 21 103 29 967
Nonsynounymous 2,435 4,035 15 52 18 500
Stopgain 6 50 0 2 0 7
Stoploss 2 5 0 0 0 1
Splicing (includes exonic) 11 20 0 0 0 2
Intronic (includes ncRNA) 3,091 4,846 22 111 35 681
5′ UTR and 3′ UTR 515 797 3 19 1 91
Downstream and upstream 51 76 1 2 1 13
Intergenic 155 259 1 2 2 40
Small indels
Altogether 278 618 89 75 88 336
Exonic (includes ncRNA) 33 99 14 11 2 29
Frameshift 9 30 4 4 1 12
Stopgain 0 1 0 0 0 0
Splicing (includes exonic) 4 16 0 4 1 3
Intronic (includes ncRNA) 212 419 64 51 75 270
5′ UTR and 3′ UTR 25 73 10 7 8 24
Downstream and upstream 1 2 0 1 1 6
Intergenic 3 9 1 1 1 4
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(Table 3). There are also other gene complexes, which are
potentially associated to cancer processes, and in different
complexes, the CD-SNVs are either somatic or germline
(Table 3).
In the case of cancer-associated small indels, the sta-
tistically most significant results were with complexes
related to RELA gene—NFKB1-RELA and RELA-REL
complexes both had p value 7.56E-4.
IVA provided the first 100 cancer-associated processes
and diseases related to CD-SNVs and small indels.
Seventy-three genes and 135 CD-SNVs were found asso-
ciated to process named as “disorder of genitourinary
system” (Table 4). These findings were present in both
the tumour and control tissues. There were also two
processes associated to bone “myelopoiesis of bone mar-
row” (associated genes NPM1, RARA) and “quantity of
trabecular bone” (associated genes CREBBP, SMO)—
these findings were present only in the tumour tissue. In
the case of small indels, all the findings were somatic
and ALK and RELA genes were associated to “outgrowthof bone marrow cells” and “inflammatory response of
bone marrow-derived macrophages”, respectively.
IVA found 111 genes with 202 germline CD-SNVs as-
sociated to cancer (Table 5). Fifteen genes, which had 43
somatic CD-SNVs were associated to “bone marrow can-
cer and tumours”. In the case of small indel, all six
genes, with a finding, are associated to cancer and the
found small indels are all somatic. The disease named as
“tumourigenesis of bone tumour” was associated to
small indel in ALK gene and was present only in the
tumour tissue.
With the osteosarcoma patient’s tumour and control
tissue, WES data IVA found six pathways associated to
CD-SNVs and six to cancer driver small indels (Table 6).
All the mutations considered here were somatic. In the
case of CD-SNVs, the statistically most significant asso-
ciation was between tumour and WNT/β-catenin signal-
ling pathway. In the case of small indels, associations
with different cytokine pathways were found. Also, a
pathway directly linked to the bone tissue—“RANK sig-
nalling in osteoclasts” was brought front.

































PRDM9 5 23527251 C/T 1/1 Loss 0/0 Normal Tolerated Probably
damaging
NM_020227.2 c.2054C > T p.T685I Exonic Missense
FOXK1 7 4722436 A/G 1/1 Loss 0/0 Normal Damaging Benign NM_001037165.1 c.497A > G p.N166S Exonic Missense
CCZ1/
CCZ1B
7 6841033 T/A 1/1 Loss 0/1 Normal Tolerated NM_198097.3 c.1228A > T p.M410L Exonic Missense
PLATa 8 42044965 G/A 1/1 Normal 0/0 Normal 2020921 Tolerated Benign NM_033011.2/ c.352C > T/ p.R118W/ Exonic Missense
NM_000930.3 c.490C > T p.R164W
AGTPBP1a 9 88292495 C/T 1/1 Loss 0/1 Normal Tolerated Benign NM_015239.2 c.292G > A p.G98R Exonic Missense
SARDH 9 136597592 T/C 1/1 Loss 0/0 Normal 149002589 Tolerated Benign NM_001134707.1, c.463A > G p.I155V Exonic Missense
NM_007101.3
FAH 15 80472526 C/T 1/1 Normal 0/1 Normal 11555096 Damaging Probably
damaging
NM_000137.2 c.1021C > T p.R341W Exonic Missense
CDC27 17 45266522 T/C 1/1 Loss 0/0 Normal 62077279 Damaging Probably
damaging
NM_001114091.1, c.17A > G p.E6G Exonic Missense
NM_001256.3




17 44632540 T/C 1/1 Gain 0/0 Normal 144051917 Activating Benign NM_001006607.2 c.4882 T > C p.W1628R Exonic Missense
ARL17A 17 44632540 T/C 1/1 Gain 0/0 Normal 144051917 Activating Benign NM_001113738.1/ c.*2182A > G/ -/ 3'UTR/
NM_016632.2 c.259 + 15585A > G - Intronic
LILRB3 19 54725835 G/C 1/1 Gain 0/0 Normal 201948566 Activating Benign NM_001081450.1, c.523C > G p.R175G Exonic Missense
NM_006864.2
Small indels
CTCFL 20 56073500 (N)103/T 1/1 Loss 0/0 Normal NM_001269041.1/ c.*4_*105del(N)103/ 3′ UTR/
NM_001269043.1/ c.1988 + 8_1988 +
109del(N)103/
Intronic/
NM_001269040.1/ c.*4_*105del(N)103/ 3′ UTR/
NM_001269042.1/ c.*4_*105del(N)103/ 3′ UTR/
NM_080618.3/ c.*4_*105del(N)103/ 3′ UTR/






















Table 2 The somatic cancer driver SNVs and small indels found in data analysis with Ingenuity Variant Analysis software (Continued)
PRR23C 3 138763627 GTGC/G 1/1 Loss 0/1 Normal 63140560 NM_001134657.1 c.-168_-166delGCA 5′ UTR
CDCA7L 7 21941867 CTTAG/C 1/1 Loss 0/0 Normal NM_001127371.2/ c.*69_*72delCTAA/ 3′ UTR/
NM_001127370.2/ c.*69_*72delCTAA/ 3′ UTR/
3′ UTR
NM_018719.4 c.*69_*72delCTAA
ALK 2 29416029 G/GATTG 1/1 Loss 0/0 Normal NM_004304.4 c.*60_*61insCAAT 3′ UTR
DSPP 4 88537081 CAGCAG
CAAT/C





RELA 11 65422086 CTC/CTG
TAGT
0/1 Loss 0/0 Normal NM_001145138.1/ c.1408delGinsACTAC/ p.E470fs*19 Exonic/ Frameshift/
NM_021975.3/ c.1417delGinsACTAC/ Exonic/ Frameshift/


























Table 3 The gene complexes which are potentially associated to cancer processes






Mucin 9.54E-05 3: MUC2, MUC4, MUC6 27 1 0
Bcl9-Cbp/p300-Ctnnb1-Lef/Tcf 2.46E-03 2: CREBBP, TCF3 2 1 0
Sox 4.55E-03 2: SOX7, SOX10 2 1 0
Cholesterol monooxygenase (side-chain-cleaving) 1.06E-02 1 1 1 0
CYP11A 1.06E-02 1 1 1 0
Sarcosine dehydrogenase 1.06E-02 1 1 1 0
Ctbp 1.59E-02 1 7 1 0
Cbp/p300 1.59E-02 1 1 1 0
Dimethylglycine dehydrogenase 1.59E-02 1 1 1 0
DRD1/5 1.59E-02 1 1 1 0
MAGI 2.64E-02 1 2 1 1
Magi-Pten 3.68E-02 1 2 1 1
Fumarylacetoacetase 1.06E-02 1 1 1 1
There are both somatic and germline cancer driver SNVs found in the tumour and control tissues.
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We applied CS to analyse CNVs in tumour and non-
tumour tissue exomes. Compared to the control tissue,
in the tumour tissue, the loss of coding sequences was
found in 6 chromosomes and 183 genes and gain of cod-
ing sequences in 4 chromosomes and 65 genes (Figure 1).
The loss or gain of coding sequences was altogether in 8
chromosomes, and the most altered were chromosomes
2 and 19 (193,701 bp and 115,358 bp, respectively;
Figure 2). The loss of heterozygosity was detected
altogether in 68 regions in 37 genes, located in 15 differ-
ent chromosomes (Additional file 3).
Integrative analysis
The integrative analysis narrows down the large list of
findings from NGS data. When combining the results
from WES data (AS, IVA, CS) and RNA-seq data [10],
we found some interesting and rather logical associa-
tions, which we would like to emphasize.
SNVs, small indels and RNA expression
To reduce down the complexity of data we received
from AS, we decided to perform as follows. In the case
of SNV data, we observed both somatic and germline
SNVs, which are homozygous in the tumour tissue and
should have an effect on translation (nonsynonymous,
stopgain, stoploss findings). Thus, we got 527 homozy-
gous germline SNVs (in 392 genes) and 8 homozygous
somatic SNVs (in 7 genes), which are located in genes
with altered expression in the tumour tissue compared
to that in the control tissue. If also considering the ljb2
database scores, seven homozygous SNVs with high
disease-causing probability remained (Table 7).In the case of small indels detected with AS, we ob-
served the somatic and germline indels, which were
homozygous in the tumour tissue. There was 52 germ-
line and 26 somatic indels in introns of the genes, which
expression pattern has also changed (data not shown).
Furthermore, there was five germline and three somatic
indels in exons of the genes with altered expression.
Thus, we found altogether three frameshift small indels,
which possibly have an effect on translation (frameshift
insertions and deletion in exons) (Table 7).
In the case of homozygous cancer driver SNVs and
small indels found with IVA (Table 2), only four genes
have altered expression pattern in the tumour tissue
compared to that in the control tissue. The mRNA ex-
pression was increased in the case of PLAT (log fold
change (logFC) = 3.65, false discovery rate (FDR; cor-
rected statistical significance) = 8.27E-27), AGTPBP1
(logFC = 0.91, FDR = 0.039) and LRRC37A3 (logFC =
1.14, FDR = 0.0072) and decreased in the case of SFB1
(logFC = −1.33, FDR = 0.0037).
CNVs, LOHs and RNA expression
When analysing the CNV results together with RNA ex-
pression results, we found that with gained copy num-
bers, there were altogether 22 genes, with altered
expression profile—20 genes with increased and 2 genes
with decreased mRNA expression. In the case of loss
copy of number, 74 genes’ expression profile had chan-
ged—11 genes with increased and 63 genes with de-
creased mRNA expression. In Table 8, the genes with
the lowest FDR values for gene expression results are
presented. Here, we would emphasize that the INSR,
which has copy number loss in area covering 174,552 bp
has also a remarkable decrease in mRNA expression
Table 4 The cancer-associated processes detected by IVA









Disorder of genitourinary system 9.05E-14 73 135 1 1
Cell biology 4.08E-04 69 132 1 1
Cell signalling 3.83E-03 25 31 1 1
Morphology of body region 2.55E-03 23 24 1 1
Abnormal morphology of cells 1.73E-03 18 19 1 1
Abnormal morphology of body cavity 6.17E-04 17 18 1 1
Morphology of body cavity 1.36E-03 17 18 1 1
Morphology of cardiovascular system 5.80E-04 13 14 1 1
Abnormal morphology of cardiovascular system 7.22E-04 12 13 1 1
Abnormal morphology of thoracic cavity 1.22E-03 11 12 1 1
Myelopoiesis of bone marrow 3.64E-03 2: NPM1, RARA 2 1 0
Quantity of trabecular bone 4.08E-03 2: CREBBP, SMO 2 1 0
Small indels
Tissue development 1.19E-03 5 5 1 0
Developmental process of tissue 1.35E-03 5 5 1 0
Development of organ 5.05E-03 4 4 1 0
Organogenesis 5.32E-03 4 4 1 0
Colony formation of tumour cell lines 6.25E-05 3 3 1 0
Colony formation of cells 4.44E-04 3 3 1 0
Colony formation 5.46E-04 3 3 1 0
Developmental process of tumour cells 3.81E-03 3 3 1 0
Colony formation of carcinoma cell lines 5.94E-05 2 2 1 0
Apoptosis of nervous tissue cell lines 2.49E-04 2 2 1 0
Outgrowth of bone marrow cells 7.56E-04 1: ALK 1 1 0
Inflammatory response of bone marrow-derived macrophages 1.26E-03 1: RELA 1 1 0
The sorting is performed by number of genes.
The bold data reflects the processes directly associated to bone.
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several genes with CNVs, which could be associated to
cancer.
Combining the LOH and mRNA expression data, we
found that in the tumour tissue, the expression of four
genes with LOH has increased significantly and expres-
sion of five genes with LOH has decreased significantly
(Table 9). The rest of the genes with LOHs had no sig-
nificant changes in mRNA expression level, and two
genes were not detected with RNA-seq (FLJ20518,
MANSC4) [10].
For additional information, please see the supplemen-
tary material as separate files for AS, IVA and CS com-
bined with RNA-seq data.
Discussion
In this study, the exome profiles of the osteosarcoma pa-
tient’s tumour and normal bone tissue were compared.Additionally, the RNA-seq data from our previous work
was used [10]. For WES data analysis, several softwares
were applied and possibly some of them are better in de-
tecting some mutations and not so effective in detecting
others. Still, we think it is more beneficial to use differ-
ent approaches and we believe it is easier to follow, if we
discuss separately the results gained from each software.
The ANNOVAR software annotated a large amount of
genes with SNVs and small indels, applying refGene
hg19 database. Over 2,700 somatic SNVs and small
indels were detected specifically in the tumour tissue,
from which almost 300 are homozygous. These findings
are located all over the exome. This demonstrates that
the changes in OS genome are not concentrated into a
single or few areas but are rather distributed.
When using ljb2 database, AS detected four homozy-
gous somatic mutations in the tumour tissue, which
could potentially cause a disease. These nonsynonymous
Table 5 The diseases associated to CD-SNVs and small indels









Cancer 7.04E-23 111 202 1 1
Tumourigenesis 8.21E-16 111 202 1 1
Cancers and tumours 3.37E-15 111 202 1 1
Organismal injury and abnormalities 9.45E-17 105 194 1 1
Carcinoma 3.46E-25 99 186 1 1
Solid tumour 2.64E-24 99 186 1 1
Epithelial neoplasia 3.34E-23 99 186 1 1
Epithelioma 3.34E-23 99 186 1 1
Breast or colorectal cancer 5.45E-23 83 164 1 1
Malignant neoplasm of abdomen 6.93E-20 83 169 1 1
Bone marrow cancer 1.69E-03 15: CREBBP, EPHA2, FGFR2,
KCNJ12, KMT2C, LILRB3, MUC17,
MUC4, MYBPC3, NPM1, RARA,
SMO, TCF3, TTN, TUBG1
43 1 0
Bone marrow cancer and tumours 1.69E-03 43 1 0
Small indels
Cancer 9.07E-03 6 6 1 1a
Hematologic cancer 2.36E-04 4 4 1 1a
Hematologic cancer and tumours 2.36E-04 4 4 1 1a
Hematological neoplasia 8.01E-04 4 4 1 1a
Lymphohematopoietic cancer 9.12E-04 4 4 1 1a
Disease of colon 7.88E-03 4 4 1 0
Hematological disease 8.15E-03 4 4 1 1a
Immunological disease 1.28E-02 4 4 1 1a
Gastrointestinal tract cancer 2.00E-02 4 4 1 0
Gastrointestinal tract cancer and tumours 2.02E-02 4 4 1 0
Tumourigenesis of bone tumour 7.04E-03 1: ALK 1 1 0
aHere, only one gene PRR23C has a small indel in heterozygous form, which most likely does not affect the gene function. See Table 2.
The bold data reflects the diseases directly associated to bone.
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http://www.humgenomics.com/content/8/1/20mutations were located in ESX1, CDC27, TMEM120B
and TMEM131. Additionally, in the case of TMEM120B
and TMEM131, the mRNA expression has decreased
substantially in the tumour tissue compared to that in
the control tissue [10]; however, further studies are
needed to confirm the possible associations between
found mutations and gene expression level. Available
data about the possible associations between OS and
these genes is very limited. In TMEM120B, a gene with
an unclear function, the mutation COSM1599921 has
been previously detected in glioma [33]. The CDC27 is a
gene possibly controlling the timing of mitosis and may
have an important role in tumour cell division [34].
In addition to the somatic mutation, the CDC27 had
33 heterozygous germline disease-causing mutations (non-
synonymous) (data not shown). In the case of breast
cancer, the CDC27 has been demonstrated to be apromising biomarker in predicting the disease progression
and prognostication [35]. Thus, these somatic mutations
may have some effect on OS pathogenesis. Especially the
abundant changes in CDC27 may be important in terms
of regulating OS tumour cell division.
In the tumour tissue, we detected homozygous som-
atic small indels causing the frameshift in five genes—
EI24, ALG1L2, TIGD6, GPATCH4 and SSPO. None of
these genes have previously been associated to OS, and
according to our RNA-seq data, only EI24 of these five
genes has altered mRNA expression—it has decreased in
the tumour tissue [10], which could be due to the inser-
tion in exon 9. The EI24 encodes a tumour suppressor
and is an immediate-early induction target of TP53-
mediated apoptosis—it binds to antiapoptotic BLC2.
Furthermore, the EI24 has found to be highly mutated
in the case of aggressive breast cancer and is rather
Table 6 The pathways associated to cancer









Wnt/β-catenin signalling 7.07E-04 6 CREBBP, RARA, SMO, SOX10, SOX7, TCF3 6 1 0
Epithelial adherens junction Ssignalling 1.26E-02 4 IQGAP1, KEAP1, TCF3, TUBG1 4 1 0
Germ cell-sertoli cell junction signalling 2.10E-02 4 GSN, IQGAP1, KEAP1, TUBG1 5 1 0
Mouse embryonic stem cell pluripotency 2.59E-02 3 CREBBP, SMO, TCF3 3 1 0
Regulation of the epithelial-mesenchymal
transition pathway
3.40E-02 4 FGFR2, SMO, TCF3, ZEB2 4 1 0
Hereditary breast cancer signalling 4.95E-02 3 CREBBP, NPM1, TUBG1 3 1 0
Small indels
IL-17A signalling in gastric cells 8.79E-03 1 RELA 1 1 0
Role of JAK1, JAK2 and TYK2 in interferon signalling 9.54E-03 1 RELA 1 1 0
Interferon signalling 9.79E-03 1 RELA 1 1 0
IL-15 production 1.00E-02 1 RELA 1 1 0
TNFR2 signalling 1.05E-02 1 RELA 1 1 0
RANK signalling in osteoclasts 2.86E-02 1 RELA 1 1 0
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http://www.humgenomics.com/content/8/1/20associated to tumour invasiveness than development of
the primary tumour [36-38]. In the present case, we found
no mutations in TP53 nor was the expression altered [10];
thus, according to this data, we may suggest that the TP53
is functional in the tumour tissue. However, the TP53Figure 1 Circos plot illustrating the CNVs and LOHs in the OS tissue c
the centre: red—gain and green—loss. LOHs are marked as dots in the cenpathway may still be suppressed due to mutated and
downregulated EI24. Moreover, the aggressive nature of
OS is correlated to this finding.
Appling Ingenuity Variant Analysis software, we found
over 200 cancer driver variants and 93% of these possiblyompared to that in the control tissue. CNVs are marked as lines in
tre: black—copy neutral, green—copy gain and red—copy loss.
Figure 2 The CNVs in chromosomes 2 and 19 in the osteosarcoma tissue compared to that in the control tissue. Data analysis performed
with CEQer software.
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http://www.humgenomics.com/content/8/1/20cause the loss of gene function. Thirteen homozygous som-
atic CD-SNVs were detected in different genes—RGPD3,
PRDM9, FOXK1, CCZ1, PLAT, AGTPBP1, SARDH, FAH,
CDC27, SBF1, LRRC37A3, ARL17A and LILRB3. The
mRNA expression of PLAT, AGTPBP1 and LRRC37A3 hasTable 7 The integrative analysis—genes with altered express
software





Germline mutations homozygous in tumour tissue
STEAP4 NM_024636—exon2: c.G364A/p.A122T 0.647
NM_001205316—exon2: c.G364A/p.A122T
NM_001205315—exon3: c.G364A/p.A122T
DDX60L NM_001012967—exon18: c.T2491C/p.C831R 0.711
MT1A NM_005946—exon3: c.A152G/p.K51R 0.785
ACOX1 NM_004035—exon7: c.C936G/p.I312M 0.872
NM_007292—exon7: c.C936G/p.I312M
NM_001185039—exon7: c.C822G/p.I274M






ATRNL1 NM_001276282—exon8: c.1399_1400insTT/p.L467fs Frameshift
insertion




TMEM131 NM_015348—exon31: c.C3947T/p.P1316L 0.945
EI24 NM_001007277—exon9: c.733dupC/p.R244fs Frameshift
insertion
These germline or somatic SNVs are all nonsynonymous and homozygous in the tuincreased and of SFB1 has decreased significantly [10]. We
found no previous data about the associations between OS
and these genes, except SBF1. With previous OS studies,
another missense mutation (p.E1539K) has detected in
SBF1 [39]. SBF1 is a SET (a nuclear oncogene) bindingion pattern [10] and SNVs annotated with ANNOVAR
Chr number Start End REF/ALT logFC FDR
Chr7 87913221 87913221 C/T 3.015 1.44E-19
Chr4 169341435 169341435 A/G 2.349 2.67E-14
Chr16 56673828 56673828 A/G −3.094 0.00795
Chr17 73949540 73949540 G/C −0.809 0.01538
Chr16 19041595 19041595 G/A 1.266 0.01726





Chr10 116931101 116931101 -/TT 2.321 0.04535
Chr12 122186317 122186317 G/A −1.548 0.00064
Chr2 98409046 98409046 G/A −0.799 0.01371
Chr11 125452300 125452300 -/C −0.815 0.01569
mour tissue and according to ljb2 database have a disease-causing effect.
Table 8 The integrative analysis—CNVs and RNA expression data [10] is observed together
CNVs RNA expression
Gene name Chr number Start End Area length CNV p value Copy number fold change logFC FDR
Loss
INSR Chr19 7119459 7294011 174,552 3.18E-11 −6.64 −3.36 9.67E-31
NFIX Chr19 13106583 13201204 94,621 0 −10.82 −2.45 1.63E-17
FARSA Chr19 13034964 13044558 9,594 0 −10.82 −2.62 1.96E-16
RAD23A Chr19 13056627 13063667 7,040 0 −10.82 −2.40 4.46E-16
GINS4 Chr8 41386724 41399418 12,694 8.28E-05 −3.94 −2.79 1.31E-15
GADD45GIP1 Chr19 13064971 13068050 3,079 0 −10.82 −2.82 3.67E-15
IFIH1 Chr2 163123588 163175218 51,630 0 −10.11 2.20 3.69E-14
RPL31 Chr2 101618690 101622885 4,195 0 −9.39 −2.05 5.08E-13
PLEKHG4B Chr5 156185 181790 25,605 1.08E-05 −4.40 −2.17 1.58E-12
ZNF358 Chr19 7581003 7581135 132 3.18E-11 −6.64 −2.59 2.56E-11
ARHGEF18 Chr19 7459998 7532004 72,006 3.18E-11 −6.64 −1.96 1.44E-10
STX10 Chr19 13255223 13260987 57,64 0 −10.82 −2.55 1.96E-10
COL5A3 Chr19 10102679 10121147 18,468 4.14E-04 −3.53 −1.92 5.45E-10
MGAT4A Chr2 99242185 99347589 105,404 0 −10.22 1.87 9.95E-10
Gain
SLC40A1 Chr2 190428309 190428951 642 1.83E-05 4.28 2.22 1.05E-14
KIT Chr4 55524094 55603446 79,352 1.69E-06 4.79 2.54 1.17E-13
PTPLAD2 Chr9 21008019 21031635 23,616 7.73E-14 7.48 3.02 4.49E-13
ATP8A1 Chr4 42571177 42629126 57,949 1.83E-07 5.22 2.65 4.54E-10
FOCAD Chr9 20658308 20993327 335,019 7.73E-14 7.48 1.94 9.12E-08
FAM200B Chr4 15683351 15692070 8,719 3.54E-05 4.14 1.83 8.59E-07
SLIT2 Chr4 20255234 20512189 256,955 4.16E-05 4.10 1.35 1.73E-05
MLLT3 Chr9 20353522 20622514 268,992 7.73E-14 7.48 1.94 2.19E-05
LCORL Chr4 17887690 18023483 135,793 4.16E-05 4.10 1.40 5.04E-05
Only the genes with lowest FDR value are presented.




LOH position Alleles LOH LOH p value logFC FDR
MS4A14 Chr11 60165358–60165379 G/C CopyNeutralLOH 0.025 2.46 3.20E-08
DSC2 Chr18 28666554–28666556 A/C CopyNeutralLOH 0.025 1.87 3.82E-07
RPS4X ChrX 71495409–71495414 G/C CopyNeutralLOH 0.01 −1.44 7.25E-07
RPS23 Chr5 81571874 A/C CopyNeutralLOH 0.005 −1.43 1.04E06
IL7R Chr5 35874575 C/T 1AlleleGain 0.025 1.59 6.69E-06
PCNXL2 Chr1 233398713 C/T CopyNeutralLOH 0.01 1.20 0.00027
HILPDA (C7orf68) Chr7 128098270 T/G CopyNeutralLOH 0.0001 −1.12 0.00094
HRNR Chr1 152188041 C/T Allele(s)Loss 0.025 −3.09 0.00796
MUC4 Chr3 195515594, 195516630 C/G CopyNeutralLOH 0.025 −2.22 0.01230
Only the genes with significant mRNA expression changes in the tumour tissue compared to that in the control tissue are presented.
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http://www.humgenomics.com/content/8/1/20factor 1 and may inhibit the cell division [40]. The de-
creased expression in the tumour tissue may be responsible
for the increased cell proliferation. Some other associations,
which might be interesting—PLAT gene is important for
cell migration and tissue remodelling and the overexpres-
sion might cause hyperfibrinolysis [41], which has not pre-
viously described in the case of OS. Two mutations in
ARL17A have detected in chondrosarcoma cells [42]. In the
case of CDC27, the same mutation (p.E6G) was also
brought front by AS as potentially disease causing, which is
discussed above. Thus, it is highly likely that at least some
of these genes participate in some level of OS pathogenesis.
Additionally, with IVA four homozygous somatic small
indels were detected in the tumour tissue. These were in
noncoding regions of genes CTCFL, PRR23C, CDCA7L
and ALK; thus, the effect might be post-transcriptional.
CTCFL is a genetic paralog of CTCF; latter is an import-
ant methylation pattern regulator. In the case of CTCF,
it has previously demonstrated that in the OS tissue, the
changes in its methylation pattern may also cause loss of
imprinting of IGF2 and H19 genes, which further alters
their expression pattern [43]. In our OS patient’s tumour
tissue, the mRNA expression of both IGF2 and H19 has
increased significantly (FDR = 3.46E-15 and FDR = 0.0015,
respectively) [10]. Thus, the association may be valid here
also. In PRR23C, one missense mutation (p.R190W) has
detected previously in the OS tissue [42]. ALK encodes a
receptor tyrosine kinase and is rearranged, mutated or
amplified in several tumours. However, in the case of OS,
there are only few reports about ALK [44,45]. In addition,
two heterozygous somatic small indels were detected in
DSPP and RELA exons; however, we found no previous
data about these findings and associations to OS. The
small indels might have an effect on the expression of
these genes both pre- and post-transcriptional level; how-
ever, these suggestions need to be further studied.
According to IVA, there were several genes with more
than one mutation—inMUC4, there were even 22 somatic
mutations in exons and 44 in introns, although they all
were heterozygous. Thus, we found MUC4 locus to be the
most altered in the tumour tissue compared to that in the
control tissue. This might explain why its mRNA expres-
sion in the tumour tissue has decreased (FDR = 0.012)
[10]. Mucin 4 is among major constituents of mucus, and
it has demonstrated that primary bone tumours rarely ex-
press MUC4 protein [46], which correlates to our finding.
Furthermore, with IVA, we found mucin complex (MUC2,
MUC4, MUC6) to have a highest significance in OS
among others. However, there are also other mucin genes
(MUC16, MUC17, MUC20) with somatic heterozygous
CD-SNVs. The expression pattern of all other detected
mucins has not changed significantly. Thus, mucins may
have a role in OS pathogenesis, but we dear not to make
any further conclusions.With IVA, there was four bone-related processes brought
front only in the case of the tumour tissue—“myelopoiesis
of bone marrow” (NPM1, RARA), “quantity of trabecular
bone” (CREBBP, SMO), “outgrowth of bone marrow cells”
(ALK) and “inflammatory response of bone marrow-
derived macrophages” (RELA). Furthermore, in disease list,
16 genes with over 40 somatic variations were associated to
“bone marrow cancer” and “bone tumour”; however, there
were also over 200 germline CD-SNVs associated to cancer.
Thus, here, we would like to emphasize that in the case of
both cancer-associated processes and diseases, the ones as-
sociated with bone are somatic mutations; however, the
findings possibly promoting cancer are germline mutations.
This is one of the phenomena, which we would like to ob-
serve in our future studies.
The most significant pathway found with IVA was
“WNT/β-catenin signalling pathway” (altered genes:
CREBBP, RARA, SMO, SOX10, SOX7, TCF3). Reviewed
in [15], the pathway is required for bone development
and has demonstrated to be altered in pathogenesis of
OS—overexpression of numerous WNT pathway com-
ponents including WNT ligands, FZDs and LRP recep-
tors and epigenetic silencing of the pathway inhibiting
genes, i.e. WIF1. However, in our previous study, we
found WNT7B and WNT11 to be downregulated and
WNT2B and WNT5B upregulated; FZD4 and FZD8 up-
regulated and LRP8 and LRP12 downregulated and
DVL3 downregulated and WIF1 and SOST upregulated.
Additionally, genes with CD-SNVs—RARA, SMO and
SOX7 were upregulated [10]. Thus, our results are rather
controversial to several previous studies demonstrating
the WNT/β-catenin pathway to be upregulated [47-49].
However, there are also studies correlating to our findings
[50,51]. As our study is based on a single case, we dear
not to conclude, why the WNT/β-catenin pathway is ra-
ther downregulated here, but we suggest the controversial
results may occur due to major heterogeneity of OS.
Nevertheless, the present study demonstrates that in
addition to altered expression patter, the genes involved in
WNT/β-catenin signalling pathway carry the CD-SNVs.
In the case of small indels, the IVA brought front the
pathways associated to RELA and these are mostly cyto-
kine signalling pathways (Table 6). Previously, it has
demonstrated that interaction of IL17A and IL17AR
promotes metastasis in OS cells. Furthermore, IL17
stimulates osteoclast resorption [52]. In our previous
study, we found IL17AR to be significantly upregulated
[10]. Osteoclasts are important in pathogenesis of OS—
the more active they are, the more aggressive the
tumour is [53]. RELA is demonstrated to enhance the
osteoclast differentiation [54]. As IVA predicts the loss
of RELA functionality (at least partially, as the small
indel is heterozygous), in the present case, the OS might
not have been as aggressive as it usually would.
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http://www.humgenomics.com/content/8/1/20Previously, it has demonstrated that chromothripsis
event is common to early stage of OS—hundreds of gen-
omic rearrangements will appear in a single instability
event [26]. In the present case, the CEQer software de-
tected nearly 2,400 gain and loss events in 8 chromosomes
involved, which should qualify as the chromothripsis.
However, the initiating cause of this massive rearrange-
ment is unknown, as there were no traumas or other en-
vironmental causes we are aware of.
In general, the gain of copy number should increase
the mRNA expression and loss of copy number should
decrease the expression [6]. In present work, this pattern
was valid in the case of 86.5% of the genes with CNVs
and altered expression. One of the strongest findings
here was the amount of CNVs in INSR, which expres-
sion has decreased remarkably (Table 8). The main
physiological role of the insulin receptor appears to be
metabolic regulation [55]. However, together with IGF1R
it forms a hybrid receptor for IGF1, latter together with
IGF2 is thought to have a key role in driving the prolifer-
ation and survival of sarcoma cells [56]. Furthermore,
the growth hormone and IGF1 axis controls the growth
and bone modelling/remodelling [57]. Additionally, the
IRS1, which is phosphorylated by the INSR, is important
for both metabolic and mitogenic pathways [58]. In the
present case, the mRNA expression of both IGF1 and
IGF2 has increased (FDR = 4.65E-35 and FDR = 3.46E-
15, respectively); however, the expression of IGF1R
remained the same in the tumour tissue compared to
that in the control tissue [10]. Furthermore, in IGF1R we
found a heterozygous germline nonsynonymous mutation
(p.G1117R) with AS, which according to ljb2 database is a
disease causing (data not shown). Similarly to INSR, the
mRNA expression of IRS1 is decreased in the tumour
tissue compared to that in the control tissue (FDR =
2.62E-10) [10]. Thus, in the present case it seems, the pro-
liferation of tumour cells might be rather supported by
increased effect of IGF1, IGF2 and IGF1R homodimer
associations, than IGF1, IGF2 and INSR-IGF1R hetero-
dimer associations or INSR effects on IRS1.
The loss of heterozygosity has been reported to be ex-
tensive in OS exomes [39]. In the present case, we did
not detect whole chromosome or gene region loss; how-
ever, we did detect the loss of heterozygosity in smaller
regions. The genes with LOH findings and increased
mRNA expression—MS4A14, DSC2, IL7R and PCNXL2
have not associated to OS previously. However, in the
case of DSC2, the overexpression has demonstrated to
be inversely correlated to bone metastasis-free survival
[59]. The mutations in IL7R exon 6 have been demon-
strated to be present in leukaemia patients’ bone marrow
samples but not associated to other solid tumours [60].
The five genes with LOHs and decreased mRNA expres-
sion—RPS4X, RPS23, HILPDA (C7orf68), HRNR andMUC4 also do not have previous information associated
to OS. Nonetheless, also the LOH analysis brought for-
ward different genes in mucin family. In addition to
MUC4, there were also other genes with LOHs but with
insignificant mRNA expression changes in the tumour
tissues—MUC2, MUC6 and MUC17. Thus, these results
also support the idea that mucins might have a role in
pathogenesis of osteosarcoma.
In summary, the present case has several characteris-
tics previously demonstrated in OS. The wide genomic
arrangements have appeared—SNVs and small indels all
over the genome and CNVs in some chromosomes; and
in several cases, these rearrangements may have an ef-
fect on gene expression. Furthermore, the germline mu-
tations seem to be associated to cancer in general and
somatic mutations to bone tumours. The most signifi-
cant pathway was the one probably most thoroughly
studied in the case of OS—the WNT/β-catenin signal-
ling pathway. We found several genes in this pathway
carrying the cancer driver variances. Additionally, the
IGF1/IGF2 and IGF1R homodimer signalling might have
an essential effect on OS pathogenesis. Which also needs
to be emphasized is that according to our data (based on
DNA and RNA studies), there is no evidence of a non-
functional TP53; however, the TP53 pathway might be
suppressed in further levels—the downregulation of
EI24. In addition, with this study, we found associations
between different genes and OS pathogenesis, which
have not demonstrated before in earlier studies. We
found the MUC4 locus to be the most altered in the
tumour tissue compared to that in the control tissue;
furthermore, several other mucin genes are also possibly
associated to OS. The somatic mutation in CDC27 was
brought front by two different data analysis softwares
and might have a role in OS pathogenesis.Conclusions
All genes, in which the mutations were detected, may be
considered as potential targets for additional studies (i.e.
functional, histopathological, clinical studies) for finding
OS biomarkers. The present study brought front the
WNT pathway genes, IGF1/IGF2 and IGF1R homodimer
signalling pathway genes, TP53 together with EI24, MUC4
together with other mucin genes and CDC27 as potential
biomarkers for OS. Finally, as this study is based on a sin-
gle case and only DNA and RNA analysis, these data may
not be taken as conclusive evidence and further studies
are needed to confirm the present findings.Additional files
Additional file 1: ANNOVAR software. The file contains the list of SNVs
(coverage at least 20 times) and small indels detected from WES study.
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nformation is added if available.
Additional file 2: Ingenuity Variant Analysis software. The file
contains the list of SNVs, which according to IVA are associated to cancer.
Additionally, the dbSNP135, SIFT and POLYPHEN functions and RNA-seq
information is added if available.
Additional file 3: CEQer software. The file contains the list of genes
where CNVs and LOHs were detected. Additionally, the RNA-seq
information is added if available.
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